Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.

Authors :: Zhang Y
Liu D
Zhang Z
Huang X
Cao J
Wang G
Du X
Wang Z
Yang M
Luo T
Liu S
Zhang W
Sheng Y
Li H
Zhang W
Chen H
Zhang S
Wang X
Meng W
Zong S
Shi M
Zheng J
Cui G
Source :: Journal of neurology [J Neurol] 2024 Jul; Vol. 271 (7), pp. 4655-4659. Date of Electronic Publication: 2024 Apr 11.
Publication Year :: 2024

Subjects :: Humans
B-Cell Maturation Antigen immunology
Immunotherapy, Adoptive methods
Female
Autoantibodies blood
Male
Middle Aged
Adult
Myasthenia Gravis immunology
Myasthenia Gravis therapy
Myasthenia Gravis drug therapy
Receptors, Cholinergic immunology
Antigens, CD19 immunology

Full Text Access

Tools